KnowTheStock
Log inCreate free account

Charles River Laboratories International Inc.

CRL
S&P 500Research and Development in Biotechnology · NEW YORK STOCK EXCHANGE INC.
$215.75last close · market cap 10.36 Billion
Compare with…
18.1SCORE / 100
Our verdictSELLWeak Growth, Earnings/Profit is NegativeQtr Ending 2026-06-27 · trend negative

Why Sell

Cash flow is moderate; income statement and balance sheet are weak.

Next earnings: 2026-11-04 (BMO), EPS Forecast: $2.98

What is strong
  • Total Debt to Total Assets Ratio is 0.35
  • Net Increase in Cash is Positive
What to watch
  • Revenue Growth is -0.74%
  • Operating Income Growth is -27.61%
  • Net Income is Negative
  • Earnings Per Share (EPS) is Negative
  • Net Margin is -5.96%
  • Current Asset to Current Liability Ratio is 1.35
  • Debt Ratio is 0.62
  • Current Debt to Net Income Ratio not available
  • Cash from Operations Growth is -26.07%
  • Capital Expenditure not available
  • Investment Risk is High

What changed

Score by quarter

Downgraded from Hold to Sell in the Jul 2023 quarter: 61.7 → 62.1 (+0.4). This quarter: +0.9.

10203040506070Sep 2022Jun 2026

What the score is made of

Income statement7.5 +0.1
Balance sheet22.3 -0.0
Cash flow47.2 +5.1

Change vs previous quarter.

Key numbers · latest quarter

Revenue (TTM)4.00 Billion-0.74 % growth
EPS-4.83
Profit margin-5.96 %Profit per $1 of sales
P-E ratio—Not available
Market cap10.36 BillionShares × price
Debt-equity ratio0.92Leverage
Dividend0.00Per share, annual
Next earnings2026-11-04BMO · EPS forecast $2.98
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.

About Charles River Laboratories International Inc.

charles river provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. #drugdiscovery #biotech #biotechnology #pharmaceuticals #cro

CEO
James Foster
Employees
12,903
Sector
Professional, Scientific, and Technical Services
Exchange
NEW YORK STOCK EXCHANGE INC.
criver.com

Similar stocks

Loading…